Sage Therapeutics (SAGE) Competitors

Sage Therapeutics (NASDAQ:SAGE) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Which has better valuation & earnings, SAGE or EBS?

Sage Therapeutics has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sage Therapeutics	$86.46M	3.61	-$541.49M	-$5.58	-0.91
Emergent BioSolutions	$1.05B	0.40	-$760.50M	-$4.10	-1.88

Do analysts rate SAGE or EBS?

Sage Therapeutics presently has a consensus target price of $12.89, indicating a potential upside of 152.72%. Emergent BioSolutions has a consensus target price of $14.00, indicating a potential upside of 81.35%. Given Sage Therapeutics' higher probable upside, equities research analysts clearly believe Sage Therapeutics is more favorable than Emergent BioSolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sage Therapeutics	2 Sell rating(s)	17 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Emergent BioSolutions	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media favor SAGE or EBS?

In the previous week, Sage Therapeutics and Sage Therapeutics both had 2 articles in the media. Sage Therapeutics' average media sentiment score of 0.85 beat Emergent BioSolutions' score of 0.30 indicating that Sage Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sage Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent BioSolutions	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is SAGE or EBS more profitable?

Emergent BioSolutions has a net margin of -18.55% compared to Sage Therapeutics' net margin of -317.29%. Emergent BioSolutions' return on equity of -9.91% beat Sage Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sage Therapeutics	-317.29%	-50.29%	-45.48%
Emergent BioSolutions	-18.55%	-9.91%	-3.31%

Do institutionals & insiders believe in SAGE or EBS?

99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer SAGE or EBS?

Sage Therapeutics received 211 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.88% of users gave Emergent BioSolutions an outperform vote while only 65.73% of users gave Sage Therapeutics an outperform vote.

Company	Underperform	Outperform
Sage Therapeutics	Outperform Votes 631 65.73%	Underperform Votes 329 34.27%
Emergent BioSolutions	Outperform Votes 420 66.88%	Underperform Votes 208 33.12%

Which has more volatility & risk, SAGE or EBS?

Sage Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Summary

Sage Therapeutics and Emergent BioSolutions tied by winning 8 of the 16 factors compared between the two stocks.